Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1867 results
September 2025
-
Featured News
Test
-
Story About Novartis Access to Healthcare
Test story page for non english content
-
Story
test story
-
Story
Test - Story - ContentSync - Translated content pulled from Repository
-
Story About Novartis
Test Content
Novartis announces the company’s financial results for the second quarter and first half of 2025.
-
Press release
Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular diseasePacibekitug is a… -
Story About Novartis Access to Healthcare
test story content
test story contenttest story contenttest story contenttest story contenttest story contenttest story contenttest story contenttest story contenttest story content
August 2025
-
Press release
Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain1 85%… -
Press release
New Novartis ESC data highlights strength of cardiovascular portfolio
Two VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol lowering monotherapyLp(a)FRONTIERS APHERESIS study will assess effect of pelacarsen on reducing… -
Press release
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients… -
Ad hoc release
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s…